Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

ARAVIVE, INC ARAV

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
40.44%

Capital & Financial Ratios

Market Cap
2.95
Revenue
7.00
Net Income
(39.85)
Free Cash Flow
(59.45)
Net Debt
(6.11)
Current Ratio
0.98
Debt/Equity
1.43
P/E ratio
0.00
P/S ratio
0.43
P/B ratio
1.78
Past 5Y EPS Growth
—
This Y EPS Growth
90.29%
Next Y EPS Growth
56.23%
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2020 2021 2022 Q'23
Cash 60.54 59.42 53.69 8.54
Receivables — 0.03 0.09 —
Inventory — — — —
Other 1.15 3.29 4.20 1.03
61.69 62.75 57.97 9.56
2020 2021 2022 Q'23
Payables 2.50 2.66 8.77 5.42
ST’ Debt 2.09 2.30 2.20 2.12
Other 4.88 12.99 11.15 2.23
9.46 17.94 22.11 9.78
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 1.49 1.27 2.76 —
—
’22 1.09 1.62 4.96 1.47
9.14
’21 0.26 3.79 2.41 0.99
7.44
’20 — — — 5.69
5.69
’19 1.70 3.05 — 0.00
4.75
’18 — — — —
1.37
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (17.75) (17.66) (9.81) —
—
’22 (12.89) (19.02) (18.93) (14.24)
(65.08)
’21 (10.02) (5.15) (8.66) (8.34)
(32.18)
’20 (4.46) (5.63) (6.30) 4.22
(12.17)
’19 (1.40) (7.21) (3.40) (5.07)
(17.08)
’18 (8.01) (7.29) (5.18) (8.78)
(29.26)
’17 (34.73) (22.08) (22.48) (37.00)
(116.29)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (17.75) (17.66) (9.81) —
—
’22 (12.89) (19.02) (18.93) (14.25)
(65.09)
’21 (10.02) (5.15) (8.66) (8.34)
(32.18)
’20 (4.46) (5.63) (6.30) 4.22
(12.17)
’19 (1.40) (7.21) (3.40) (5.07)
(17.08)
’18 (8.01) (7.29) (5.18) (8.81)
(29.29)
’17 (34.73) (23.09) (25.00) (37.77)
(120.59)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.66) (0.12) 0.28 —
—
’22 (0.62) (0.61) (0.51) (0.46)
(2.10)
’21 (0.44) (0.35) (0.53) (0.62)
(1.95)
’20 (0.72) (0.32) (0.66) (0.25)
(1.93)
’19 (0.42) (0.27) (0.54) (0.35)
(1.57)
’18 (1.50) (1.62) (1.08) (4.82)
(10.64)
’17 (5.10) (6.24) (8.40) 5.22
(14.46)

Target Price Range

High
—
‡‡‡‡
Average
—
‡‡‡‡
Low
—
‡‡‡‡

Recommendation Rating

2.5
1
Buy
2
3
Hold
4
5
Sell
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
— — — — — — — — — — — — —
Low Price
— — — — — — — — — — — — —
High Price
— — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 23 — — —
Employees
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.40 — — —
Revenue/Emp
— — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.14 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% — — —
Gross Margin
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (76.32) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EBT
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (835.31%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (76.32) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.89 — — —
Depreciation
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 0.25 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.10) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.79) ‡‡‡ — —
Cash Flow/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.79) — — —
Free CF/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.29 ‡‡‡ — —
Book Value/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 36.37 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — — — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.14 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.40 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.29) ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.04 — — —
EV/FCF
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (65.08) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — — — (0.01) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capex
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (65.09) ‡‡‡ — —
FCF
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 35.86 — — —
Working Cap'
— — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.08 — — —
Total Debt
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (49.61) — — —
Net Debt
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.66 — — —
Sh' Equity
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (117.47%) ‡‡‡ ‡‡‡ ‡‡‡
ROA
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00% — — —
ROIC
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (288.67%) ‡‡‡ ‡‡‡ ‡‡‡
ROE
predictions in italic, sparklines do not include predictions

ARAVIVE, INC (ARAV) Latest News

News by impact score

Fine-tune

No news matches these filters.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us